Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. 

<p>Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. </p>


Prime Medicine

Patent Agent 

Director, Intellectual Property

More beef in the gene editing space - STAT

#WilsonDisease currently has no cure and requires lifelong treatment. Today, on #WilsonDiseaseAwarenessDay, we stand with those whose lives have been upended by this disease, and are proud to be working to offer improved treatment options to those in need. #WilsonDiseaseAwareness

Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus

 Prime Medicine initiated with bullish view at JMP Securities, here's why 

Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha


												8_31_23
												Cell												Phage-assisted evolution and protein engineering yield compact, efficient prime editors
												Jordan L. Doman, Smriti Pandey, Monica E. Neugebauer, Meirui An, Jessie R. Davis, Peyton B. Randolph, Amber McElroy, Xin D. Gao, Aditya Raguram, Michelle F. Richter, Kelcee A. Everette, Samagya Banskota, Kathryn Tian, Y Allen Tao, Jakub Tolar, Mark J. Osborn & David R. Liu											

 Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics 

Prime Medicine drops after cutting CGD program amid restructuring - MSN

Over 300M people across the globe are affected by a rare disease, and only 5% of those diseases have approved treatments. Prime is proud to be part of the community working to change that.

This week, we recognized #RareDiseaseDay and honored patients & families by hosting a showing of Emmy-nominated documentary Rare in Common, sharing rare disease books and resources across offices, and wearing our stripes. 🦓

Prime to narrow gene editing research as it strikes deal with Bristol Myers - BioPharma Dive

 Form 424B5 Prime Medicine, Inc. 

Investors_

 FDA clears Prime Medicine to begin gene therapy clinical testing 

 FDA Clears Prime Medicine's IND for First Prime Editing Therapy 

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? - Yahoo Finance

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Yahoo Finance

 Prime Medicine GAAP EPS of -$0.44 beats by $0.03, revenue of $0.59M misses by $0.32M 

A radiopharmaceuticals startup raises $175 million - STAT

Prime Medicine Reports Q3 2024 Financial Progress - TipRanks

The FDA Has Cleared the First Clinical Trial Application for a Prime Editor - CRISPR Medicine News

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Prime Medicine soars as it inks research collab with BMS - The Pharma Letter

 Is prime editing ready for prime time? 

Prime Medicine Executives Make Bold Stock Purchases! - TipRanks

Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks

At a time when biotech business trends are uncertain and many patients are still waiting on new treatments, many may ask, where does #CRISPR go from here? Prime CEO Keith Gottesdiener looks forward to addressing this during the Endpoints News Catalysts event alongside other industry leaders this month. Register for the free, virtual event here. https://lnkd.in/g--qQNPg

 Prime Medicine to Participate in Upcoming Investor Conferences 

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb - MarketWatch

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot - BioPharma Dive

 ASGCT24: Prime Medicine to Apply Gene Editing to Wide-Ranging Indications 

View More_

Prime Medicine stock a top pick for gene editing, says JMP Securities - Investing.com

 Prime Medicine reports Q3 EPS (44c), consensus (44c) 

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN

Prime Medicine Secures $55 Million Deal with Bristol Myers Squibb to Develop Next-Gen T-Cell Therapies - SynBioBeta

 Prime Medicine GAAP EPS of -$0.46 misses by $0.05 

Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire


												6_22_20
												nature biotechnology												Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
												Andrew V. Anzalone, Luke W. Koblan & David R. Liu											

 Why Prime Medicine Stock Is Soaring Today 

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? - Yahoo Finance

 Prime Medicine 19.2M share Spot Secondary priced at $6.25 


						3_18_25
						Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
					

 Prime Medicine outlines plans for gene editing pipeline 

BMS pays Prime $110M to form T-cell therapy pact

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb - STAT

Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? - Yahoo Finance

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Benzinga

 Prime editing comes of age as FDA clears human trials 


												10_4_21
												nature biotechnology												Engineered pegRNAs improve prime editing efficiency
												James W. Nelson, Peyton B. Randolph, Simon P. Shen, Kelcee A. Everette, Peter J. Chen, Andrew V. Anzalone, Meirui An, Gregory A. Newby, Jonathan C. Chen, Alvin Hsu & David R. Liu											

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Prime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term Volatility - TipRanks

 The Top 7 Biopharma Licensing Deals of 2024 

Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25% - Stock Plunges - Nasdaq

 Broad, Harvard researchers win Breakthrough Prize, known as 'Oscars of Science' 

 Gene-editing firm Prime Medicine files $140m public offer 

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com

PKU in mice treated with base and prime editing

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique - BioSpace

Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com Nigeria

 Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers 

 Prime Medicine (PRME) Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency 

Prime Medicine Files for Resale of 11 Million Shares - Marketscreener.com

 Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to ... 

 Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics 

Prime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a Buy - TipRanks

Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

Prime Medicine stock target cut to $6 by JMP Securities - Investing.com

 Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates 

Prime Medicine Reports Q1 2025 Financial Results - TipRanks

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies - GlobeNewswire


						5_19_25
						Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
					

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

 Prime Medicine to Cut Costs, Focus on Liver Treatment Programs; New CEO Named 


						11_12_24
						Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
					

Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) - GlobeNewswire


						11_6_24
						Prime Medicine to Participate in Upcoming Investor Conferences
					

Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - The Motley Fool

 Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference 

Prime and Beam, born of same lab, pursuing rival gene-editing treatments - statnews.com

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan

Prime Medicine initiated with an Outperform at JMP Securities - MSN

 Chardan Capital Maintains Buy on Prime Medici... 

 Prime Medicine to Present at Upcoming Investor Conferences 

The biotech news you need to read today - STAT

Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat

 Prima Medicine Welcomes Dr. Mandana Shafai to Its Expanding Concierge Medicine Program in Northern Virginia 

Prime Medicine

Business:

About: